ALK and non-small cell lung carcinoma: Previous systematic reviews of ALK inhibitors for the treatment of NSCLC have reported improved overall and progression-free survival with crizotinib and alectinib compared with chemotherapy.[6, 7] However, previous reviews were limited by the use of a pair-wise meta-analysis approach, which permits comparison of only two therapies at one time (e.g., alectinib v.